Skip to content

Rheumatoid arthritis — treat to target and remission

TL;DR — Treat-to-target is a strategy, not a drug: measure disease activity frequently, aim for remission or at least low activity, and adjust therapy until the target is sustained. In TICORA, 111 patients randomized to intensive management or routine care had better clinical and radiographic outcomes with tight control (Grigor 2004, PMID 15262104). Composite targets improve consistency but mix inflammatory and non-inflammatory domains; DAS28 remission is less stringent than SDAI or Boolean remission. The 2022 ACR/EULAR Boolean revision allows patient global assessment ≤2/10 while retaining tender joints, swollen joints, and CRP ≤1 (Studenic 2023, PMID 36274193). Imaging-driven escalation has not improved outcomes over clinical tight control, and tapering increases flare risk, so sustained remission must be demonstrated rather than inferred (Mandl 2019, PMID 31518423; Tascilar 2021, PMID 38297524).

Strategy components

Component Operational requirement
Explicit target Remission; low disease activity if remission is not feasible
Valid measure DAS28, SDAI, CDAI or Boolean criteria
Frequent assessment Short intervals in active disease
Timely adjustment Escalate or switch when trajectory misses target
Shared decision Balance efficacy, risk, burden and priorities
Sustainment Confirm target over time before tapering
Domain separation Distinguish inflammation from pain, fatigue and damage

TICORA showed that structured intensive management can improve outcomes even using older DMARDs, establishing strategy as an active intervention (Grigor 2004, PMID 15262104). FIN-RACo similarly showed that early aggressive combination therapy reduced five-year joint damage (Korpela 2004, PMID 15248204).

Activity measures

Measure Components Common target Key limitation
DAS28-ESR 28 tender/swollen joints, ESR, patient global remission <2.6 Omits feet/ankles; ESR weighting; residual swelling possible
DAS28-CRP 28 joints, CRP, patient global formula-specific Not interchangeable with DAS28-ESR
SDAI TJC28, SJC28, patient/clinician global, CRP remission ≤3.3 Requires CRP
CDAI TJC28, SJC28, patient/clinician global remission ≤2.8 No laboratory component
Boolean 2.0 TJC28≤1, SJC28≤1, CRP≤1 mg/dL, PtGA≤2/10 all four Stringent; still omits feet

The 2022 revision addressed discordance caused by a PtGA threshold of 1/10; raising it to 2 improved agreement with index remission without materially weakening prediction of good function and radiographic outcome (Studenic 2023, PMID 36274193).

What the target should be

A systematic review/meta-regression found T2T superior to usual care but could not establish one universally optimal target across measures and cutoffs (Messelink 2023, PMID 37116986). Remission is preferred because damage and disability track cumulative inflammation, but low disease activity is reasonable in established damage, comorbidity, or treatment-limiting toxicity.

Situation Target interpretation
Early RA Pursue remission rapidly; structural prevention potential is greatest
Longstanding damaged joints Tenderness/function may not normalize with immunosuppression
Fibromyalgia/central pain Patient global and tenderness may stay high without synovitis
Recurrent infection/frailty Lowest safe activity may be more appropriate than maximal escalation
Persistent swollen joints Objective inflammation remains off-target even if global score is low
Pregnancy planning Target plus treatment compatibility both matter

Monitoring intervals and response

EULAR recommends treatment adjustment when improvement is insufficient by three months or target is not reached by six months, interpreted by trajectory and prognostic factors (Smolen 2023, PMID 36357155). ACR emphasizes rapid methotrexate titration and minimizing glucocorticoids (Fraenkel 2021, PMID 34101376).

Response measures describe change; activity states describe current status. ACR20/50/70 are useful trial outcomes but are not clinical targets: a patient can improve 50% and still have high disease activity.

Imaging and subclinical inflammation

Ultrasound and MRI frequently detect inflammation during clinical remission. However, strategy trials comparing imaging-targeted with clinical-targeted care have not demonstrated added clinical benefit and can drive more treatment (Mandl 2019, PMID 31518423). Imaging is valuable for a specific diagnostic question—discordant examination, tendon disease, occult synovitis—not as an automatic escalation target.

Residual symptoms at target

A systematic review of 55 reports found substantial pain, fatigue and functional limitation among patients meeting activity targets (Michaud 2021, PMID 32619340). Persistent symptoms can arise from damage, osteoarthritis, fibromyalgia, neuropathy, sleep disturbance, mood, obesity or deconditioning.

Discordance Likely next step
High symptoms + swollen joints/CRP Reassess inflammatory treatment
High symptoms + no objective inflammation Evaluate non-inflammatory contributors
Low symptoms + persistent swelling Do not assume remission
Normal CRP + active swelling Use clinical examination; IL-6 blockade may suppress CRP
Ultrasound signal + clinical remission Interpret in context; routine escalation unsupported

Tapering and drug-free remission

RETRO randomized patients in stable remission to continue, taper, or stop DMARDs; relapse increased with reduction and particularly withdrawal (Tascilar 2021, PMID 38297524; Haschka 2016, PMID 25660991). TARA found no clear advantage to tapering conventional DMARD or TNF inhibitor first over two years; flares were common in both strategies (van Mulligen 2020, PMID 32482645).

Taper principle Evidence-informed rationale
Require sustained remission Single-visit remission is unstable
Reduce gradually Enables early reversal
Avoid abrupt all-DMARD withdrawal Highest flare risk
Monitor frequently Flares often recover if detected promptly
Include patient preference Burden, fear and toxicity differ
Document structural risk Erosive/seropositive disease may tolerate flare poorly

Strategy effect sizes and target controversy

Strategy trial Quantified result Lesson
CAMERA At least one remission period occurred in 50% with monthly computer-assisted methotrexate escalation versus 37% with conventional three-monthly care (p=0.03; n=299) (Verstappen 2007, PMID 17519278). Measurement cadence and protocolized adjustment can change outcomes without changing the anchor drug.
BeSt At three months, mean HAQ was 0.6 with initial prednisone- or infliximab-based combination versus 1.0 with sequential/step-up therapy (p<0.001); one-year median Sharp progression was 0.5–1.0 versus 2.0–2.5 (p<0.001) (Goekoop-Ruiterman 2005, PMID 16258899). Rapid suppression improves early function and structure, but all arms were repeatedly adjusted to a target.
ARCTIC imaging target Primary composite achieved by 22% with ultrasound-tight control versus 19% with clinical tight control; difference 3.3% (95% CI −7.1 to 13.7) (Haavardsholm 2016, PMID 27530741). Adding imaging remission did not improve outcomes despite more intensive surveillance.
TaSER imaging target DAS44 change was −2.69 with ultrasound-driven versus −2.58 with DAS28-driven care; between-group 95% CI −0.70 to 0.48 (p=0.72), with no imaging advantage (Dale 2016, PMID 27026689). More treatment for Doppler activity did not deliver a clear net clinical benefit.
Systematic monitoring Review of controlled strategy studies found outcome improvement when validated activity measures drove escalation (Katchamart 2010, PMID 20436069). The actionable component is a prespecified response to measurement, not measurement alone.

Treat-to-target therefore has two boundaries. First, a composite dominated by tenderness or patient global may prompt immunosuppression when inflammation is already controlled. Second, a more “objective” imaging target can also overtreat subclinical signal. TICORA and TEAR syntheses emphasize that intensive management is a care process—frequent review, adherence work, rapid adjustment and shared decisions—not a single score (Porter 2012, PMID 23078791).

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Wang W, et al. Side effects of methotrexate therapy for rheumatoid arthritis: systematic review. Eur J Med Chem. 2018. (PMID 30243154) Adjacent evidence from classification-and-diagnosis.md, conventional-dmards.md, epidemiology-and-burden.md, overview.md
Hazlewood GS, et al. Methotrexate monotherapy and combination therapy: Cochrane network meta-analysis. BMJ. 2016. (PMID 27102806) Adjacent evidence from conventional-dmards.md
Katchamart W, et al. Methotrexate monotherapy versus non-biological DMARD combinations. Ann Rheum Dis. 2009. (PMID 19054823) Adjacent evidence from conventional-dmards.md
van Vollenhoven RF, et al. SWEFOT one-year randomized trial. Lancet. 2009. (PMID 19665644) Adjacent evidence from clinical-trials-landscape.md, conventional-dmards.md
Bijlsma JW, et al. Glucocorticoids in treatment of RA. Clin Exp Rheumatol. 2015;33:S34-S36. (PMID 26457916) Adjacent evidence from conventional-dmards.md
Ling SF, et al. Pharmacogenetics of methotrexate response in RA. 2020. (PMID 31849277) Adjacent evidence from biomarkers-and-tissue-precision.md, conventional-dmards.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Kerschbaumer A, et al. DMARD efficacy review informing EULAR 2022. Ann Rheum Dis. 2023. (PMID 36368906) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, guidelines.md, overview.md
England BR, et al. 2022 ACR guideline for exercise, rehabilitation, diet and integrative interventions in RA. Arthritis Rheumatol. 2023. (PMID 37227116) Adjacent evidence from guidelines.md
Peter WF, et al. Clinical practice guideline for physical therapist management of RA. Phys Ther. 2021. (PMID 34003240) Adjacent evidence from guidelines.md
Nagy G, et al. EULAR points to consider for management of difficult-to-treat RA. Ann Rheum Dis. 2022. (PMID 34407926) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md, guidelines.md
Saavedra AA, et al. RA-ILD treatment: appraisal of 2023 ACR/CHEST guideline. 2025. (PMID 39822854) Adjacent evidence from guidelines.md, ra-associated-interstitial-lung-disease.md
Fautrel B, et al. 2024 French Society recommendations for RA diagnosis and management. 2024. (PMID 39389412) Adjacent evidence from guidelines.md
Abud-Mendoza C, et al. Mexican College of Rheumatology RA guideline 2023. 2024. (PMID 38796394) Adjacent evidence from guidelines.md
Harigai M, et al. 2024 Japan College of Rheumatology RA guideline update. 2025. (PMID 39820350) Adjacent evidence from guidelines.md
Conley B, et al. Core recommendations for RA care: systematic review of guidelines. 2023. (PMID 37291382) Adjacent evidence from guidelines.md
Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib. N Engl J Med. 2022. (PMID 35081280) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md, guidelines.md, jak-inhibitors-and-targeted-therapy.md, overview.md, red-flags-and-safety-concerns.md
Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021. (PMID 33004335) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md, epidemiology-and-burden.md, overview.md
Buch MH, et al. Persistent inflammatory and non-inflammatory mechanisms in refractory RA. Nat Rev Rheumatol. 2021. (PMID 33293696) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Which remission definition best predicts drug-free control rather than merely good current status?
  • Can tissue or blood biomarkers distinguish suppressive from restorative remission? (Rivellese 2022, PMID 35589854)
  • What monitoring schedule minimizes flare damage during tapering? (Tascilar 2021, PMID 38297524)
  • How should patient global assessment be interpreted when inflammation is controlled but pain persists? (Studenic 2023, PMID 36274193)
  • Does targeting tenosynovitis or feet add value without overtreatment?

References

  1. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  2. Studenic P, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023;75:15-22. PMID 36274193
  3. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  4. Tascilar K, et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 2021;3:e767-e777. PMID 38297524
  5. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204
  6. Messelink MA, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9:e003196. PMID 37116986
  7. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18. PMID 36357155
  8. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108-1123. PMID 34101376
  9. Michaud K, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73:1606-1616. PMID 32619340
  10. Haschka J, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:45-51. PMID 25660991
  11. van Mulligen E, et al. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79:1174-1181. PMID 32482645
  12. Verstappen SM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-9. PMID 17519278
  13. Goekoop-Ruiterman YP, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90. PMID 16258899
  14. Haavardsholm EA, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016;354:i4205. PMID 27530741
  15. Dale J, et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75:1043-50. PMID 27026689
  16. Katchamart W, et al. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol. 2010;37:1411-5. PMID 20436069
  17. Porter D, et al. Intensive management of early rheumatoid arthritis: the TICORA and TEAR studies. Clin Exp Rheumatol. 2012;30:S32-4. PMID 23078791
  18. Wang W, et al. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502-516. PMID 30243154
  19. Hazlewood GS, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. PMID 27102806
  20. Katchamart W, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105-12. PMID 19054823
  21. van Vollenhoven RF, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459-66. PMID 19665644
  22. Bijlsma JW, et al. Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:S34-6. PMID 26457916
  23. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  24. Kerschbaumer A, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82:95-106. PMID 36368906
  25. England BR, et al. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023;75:1603-1615. PMID 37227116
  26. Peter WF, et al. Clinical Practice Guideline for Physical Therapist Management of People With Rheumatoid Arthritis. Phys Ther. 2021;101:pzab127. PMID 34003240
  27. Nagy G, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81:20-33. PMID 34407926
  28. Saavedra AA, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. Curr Treatm Opt Rheumatol. 2024;10:43-60. PMID 39822854
  29. Fautrel B, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Joint Bone Spine. 2024;91:105790. PMID 39389412
  30. Abud-Mendoza C, et al. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023. Reumatol Clin (Engl Ed). 2024;20:263-280. PMID 38796394
  31. Harigai M, et al. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. Mod Rheumatol. 2025;35:387-401. PMID 39820350
  32. Conley B, et al. What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clin Rheumatol. 2023;42:2267-2278. PMID 37291382
  33. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  34. Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31-35. PMID 33004335
  35. Buch MH, et al. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17-33. PMID 33293696
  36. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854